NOV 11, 2015 12:00 PM PST

Cholesterol Treatment Guidelines: Controversies and use in clinical practice

Speaker

Abstract

In November of 2013 the AHA/ACA jointly proposed new guidelines for the management of hypercholesterolemia, the first full update in over a decade.  The charge was to create evidence based recommendations, whenever possible based on randomized clinical trials and meta-analysis of such trials. The finished product proposed a major paradigm shift in management. Still emphasizing the importance of risk assessment for determining treatment initiation, four groups were identified that would benefit from moderate or high intensity statin therapy in order to achieve cardiovascular risk reduction. Recommendations based the decision regarding moderate or high intensity therapy on the level of cardiovascular risk balanced against risks of intensive therapies. Controversies included elimination of previously proposed and long accepted LDL-C and non-HDL-C treatment goals, a new tool for risk stratification in primary prevention populations and de-emphasis of non-statin therapies. The guidelines did offer an extensive review of cholesterol altering medications and their risks and benefits, expert opinion on how to deal with statin intolerance, recommendations for the use of biomarkers/noninvasive testing in risk assessment and promised swifter integration of new data into future guidelines. However, limiting recommendations to clinical trials also may limit therapeutic recommendations for individuals falling outside these four treatment groups. Concerns were raised about both over treatment and under treatment in certain populations. A careful review of the published statement can address some of the controversies but others still exist. Newer studies with conventional therapies and recently approved therapies may soon trigger a rethinking of the guidelines particularly relative to goals for therapy and combination therapies with statins. Objectives are to review the details of the 2013 guideline, highlight the weaknesses and strengths of the guideline and discuss utilization of these recommendations in current practice.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
NOV 11, 2015 12:00 PM PST

Cholesterol Treatment Guidelines: Controversies and use in clinical practice



Show Resources
Loading Comments...
Show Resources